The retreatment data strengthens the case for Descartes-08's durability and safety, de-risking the upcoming Phase 3 AURORA readout in Q1 2027. Monitor for any competitive updates from other CAR-T or autoimmune therapies targeting MG, and watch for potential partnership or financing announcements ahead of the BLA filing.
Price Chart
Executive Summary
Cartesian Therapeutics announced additional positive retreatment data for its lead CAR-T candidate, Descartes-08, in myasthenia gravis (MG) at the AANEM Annual Meeting. The data from 5 retreated patients showed a mean MG-ADL reduction of 6.6 points at Month 12, with no new safety signals. Topline results from the Phase 3 AURORA trial are expected in Q1 2027, with a BLA filing anticipated in mid-2027.
Key Facts
- Retreated patients (n=5) showed a mean MG-ADL reduction of 6.6 points at Month 12 following retreatment.
- Median interval between end of initial treatment and first retreatment infusion was 16.6 months.
- No new safety signals; no cases of CRS, ICANS, cytopenias, or hypogammaglobulinemia reported.
- Topline data from Phase 3 AURORA trial of Descartes-08 in MG expected in Q1 2027.
- BLA filing for Descartes-08 in MG expected in mid-2027.
- Descartes-08 has RMAT and Orphan Drug Designation from FDA for MG.
- FDA agreed under SPA that Phase 3 AURORA trial design is acceptable to support a future BLA.
Financial Impact
No financial figures disclosed; clinical-stage biotech with no approved products or revenue.
Risk Factors
- Phase 3 AURORA trial results could fail to meet endpoints, potentially delaying or ending the program.
- Regulatory approval and commercial launch risks remain binary; SPA agreement does not guarantee approval.
- Competing therapies (e.g., other CAR-T, FcRn inhibitors) could erode market opportunity.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001453687-26-000105 |
| Document: 0001453687-26-000105-index-headers.html | 0001453687-26-000105 |
| Document: 0001453687-26-000105-index.html | 0001453687-26-000105 |
| Document: 0001453687-26-000105.txt | 0001453687-26-000105 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $7.24 $7.21 | ▼ −0.41% | ▼ −0.21% | $6.28 (−13.26%) |
Aug 6, 2026 11w ago | 8-K | $8.76 $8.85 | ▲ +1.03% | ▲ +0.42% | $6.28 (−28.31%) |
May 26, 2026 21w ago | 8-K | $5.84 $5.86 | ▲ +0.34% | ▲ +0.12% | $6.28 (+7.53%) |
May 26, 2026 21w ago | Press Release | $6.45 $6.93 | ▲ +7.44% | ▲ +7.43% | $6.28 (−2.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers